StockData
Vistagen Therapeutics, Inc. logo

Vistagen Therapeutics, Inc. (VTGN) stock

VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3073% below fair value
$0.18+0.00 (+0.95%)

Close on Nov 13, 2026Market cap $8.01MP/E –Yield –

Earnings

Vistagen Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 11, 2027
Q3 FY2027 · estimated, after the close
Revenue, Q2 FY2027
$138.00K
-46.5% on a year earlier
EPS, Q2 FY2027
-$0.24
-$0.54 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Vistagen Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2027ended Dec 31, 2026Feb 11, 2027Expected––––
Q2 FY2027ended Sep 30, 2026Nov 13, 2026after the close$138.00K-46.5%-$0.24Release
Q1 FY2027ended Jun 30, 2026Aug 14, 2026before the open–––Release
Q4 FY2026ended Mar 31, 2026Jun 15, 2026after the close–––Release
Q3 FY2026ended Dec 31, 2025Feb 12, 2026after the close–––Release
Q2 FY2026ended Sep 30, 2025Nov 13, 2025after the close$258.00K–-$0.54Release
Q1 FY2026ended Jun 30, 2025Aug 7, 2025after the close–––Release
Q4 FY2025ended Mar 31, 2025Jun 17, 2025after the close–––Release
Q3 FY2025ended Dec 31, 2024Feb 13, 2025after the close$234.00K-43.1%-$0.46Release
Q2 FY2025ended Sep 30, 2024Nov 7, 2024after the close–––Release
Q1 FY2025ended Jun 30, 2024Aug 13, 2024after the close$84.00K-52.7%-$0.35Release
Q4 FY2024ended Mar 31, 2024Jun 11, 2024after the close–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Vistagen Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Vistagen Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Vistagen Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update
    Results
  2. Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder
    News
  3. 8-K exhibit EX-99.1
    Update
  4. Vistagen Reports Positive Findings Supporting Fasedienol’s Potential
    News
  5. Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
    News
  6. Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
    Results
  7. Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for
    Update
  8. Vistagen Appoints Douglas J. Williamson to its Board of Directors
    Update
  9. Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
    Update
  10. 8-K exhibit EX-99.2
    Update
  11. Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
    Results
  12. Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
    News
  13. Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
    Update
  14. Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
    News
  15. Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
    News

See a number that looks wrong?